Search PubMed⌕ Search

Biomedical subjects

M Terunuma

Publications and source records attributed to M Terunuma.

24 records · Page 2Linked to original sources
PubMed1994

[Endoscopic hydrocele fulguration].

We used an endoscopic technique for the treatment of three relatively large hydroceles in which the capacity of intra-cele fluid was suspected to be 200 ml and more. Modified laparoscopic trocar was inserted into the hydrocele. The resectoscope with a 30-degree lens was inserted via the trocar into the hydrocele. With video monitoring and continuous flow of irrigant, the parietal surface of the hydrocele was completely fulgurated. The resectoscope was then removed and a Penrose drain was placed through the trocar into the sac. The trocar was removed over the drain and the drain was secured in place. Although postoperative convalescence was not minimal, the patients were receptive well. This technique was useful for the treatment of three relatively large hydroceles.

Aged↗
PubMed1992

[Successful local adoptive immunotherapy for pleuritis carcinomatosa due to renal cell cancer. A case report].

A 54-year-old woman who had undergone radical nephrectomy for renal cell cancer nine months before was admitted to our hospital because of difficulty in breathing. X-ray films of the chest showed massive pleural effusion on the left side and cytological examination of the effusion revealed malignant cells which may have originated from renal cell cancer. Intrapleural instillations of interleukin-2 and of tumor infiltrating lymphocytes isolated from the pleural effusion were performed. After the initiation of the treatment, the pleural effusion decreased and malignant cells disappeared from the pleural fluid. Partial response defined by the criteria provided by the Japan Lung Cancer Society was achieved. No serious side effects were observed. This would be a useful treatment for pleuritis carcinomatosa by renal cell cancer.

Carcinoma, Renal Cell↗
PubMed1992

[MRI of pheochromocytoma--comparison with CT, 131I-MIBG, urinary catecholamine level and operative findings].

16 patients (7 male, 9 female) ranging in age from 13 to 71 (44.1 +/- 18.4) years old with clinically diagnosed pheochromocytoma were prospectively evaluated with CT (N = 16), MRI (N = 16), 131I-MIBG (N = 10) and operative findings in order to evaluate their diagnostic efficacy. 1. Normal adrenal glands appeared less intense than the liver on T1-weighted image (T1WI), less intense than or isointense with the liver on both proton density image (PDI) and T2-weighted image (T2WI). 2. Pheochromocytomas with high urinary noradrenaline level appeared less intense than the liver on T1WI, more intense on T2W1 and showed accumulation of radioisotope on 131I-MIBG scintigraphy. In cases with normal urinary noradrenaline level, they appeared less intense than or isointense with the liver on all pulse sequences (T1WI, PDI and T2WI). 3. Although diagnostic accuracy of localization was 81.3% (13/16) by CT, 93.8% (15/16) by MRI and 90% (9/10) by 131I-MIBG scintigraphy, MIBG scintigraphy showed higher diagnostic ability in cases with multiple lesions or recurrent tumors.

3-Iodobenzylguanidine↗
PubMed1992

[Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].

Twenty cases (fourteen males, six females, mean age 66.0) with locally advanced (T2-4 N0, M0, n = 9) or metastatic (N2-3 or M1, n = 11) urothelial cancer were treated sequentially with methotrexate (MTX) and 5-fluorouracil (5-FU), Doxorubicin (ADM), and cisplatin (CDDP) since August, 1988. Primary tumors were in the bladder in fifteen patients and in the renal pelvis or ureter in five cases. Histological findings were adenocarcinoma in one and transitional cell carcinoma in the other cases. Histological grades were grade 2 in four, grade 3 in fifteen, poorly differentiated adenocarcinoma in one. Seven patients were treated by neoadjuvant chemotherapy. Three were treated for recurrent lesions. Ten were treated for the unresectable disease. The patients received one to four cycles of this regimen (average: 2.8 cycles). Complete clinical response was observed in seven of twenty patients (35%) with measurable indicator lesions. Seven patients (35%) had a partial clinical response. Significant tumor regression was noted in fourteen of twenty patients (70%) in total, in eight of ten (80%) treated with full dose chemotherapy. The group of full dose chemotherapy showed an improved trend in survival rate as compared with the group treated by 80% and less dose chemotherapy. Toxicity was relatively mild, with anemia, leukopenia, thrombocytopenia, and no drug related death. The results suggest that the combined chemotherapy with sequential MTX and 5-FU, ADM, and CDDP is remarkably effective on advanced urothelial cancer.

Adenocarcinoma↗
PubMed1992

[A case of advanced ureteral squamous cell carcinoma showing complete response to combination chemotherapy with cisplatinum, vindesine, and bleomycin].

A 56-year-old Japanese female was diagnosed as advanced squamous cell carcinoma of the left ureter, stage IV (T4N0M0), and treated with anti-cancer drugs using cis-platinum, vindesine, and bleomycin. The tumor vanished after the treatment. The specimen after left total nephroureterectomy and hysterectomy showed only granulomatous change with necrosis and foreign giant cells but not cancer cells.

Antineoplastic Combined Chemotherapy Protocols↗